APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: Data from the Strong Heart Study. Issue 12 (10th February 2022)

• Record Type: Journal Article
• Authors: Suchy‐Dicey, Astrid; Howard, Barbara; Longstreth Jr, WT; Reiman, Eric M.; Buchwald, Dedra
• Is Part Of: Alzheimer's & dementia. Volume 18:Issue 12(2022)
• Page Start: 2518
• Page End: 2526
• Publication Date: 2022-02-10
• Subjects: Alzheimer's disease -- APOE genotype -- cerebral atrophy -- cognitive impairment -- vascular dementia; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.12573
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: The apolipoprotein E ( APOE ) ε4 allele confers higher risk of neurodegeneration and Alzheimer's disease (AD), but differs by race/ethnicity. We examined this association in American Indians. Methods: The Strong Heart Study is a population‐based cohort of American Indians who were 64 to 95 years of age in 2010 to 2013. APOE ε4 status, brain imaging, and neuropsychological testing was collected in N = 811 individuals. Summary statistics, graphics, and generalized linear regressions—adjusted for sociodemographics, clinical features, and intracranial volume with bootstrap variance estimator—compared APOE ε4 carriers with non‐carriers. Results: APOE ε4 carriers comprised 22% of the population (0.7% homozygotes). Participants were mean 73 years, 67% female, and 54% had some college education. The majority were obese (>50%), hypertensive (>80%), and diabetic (>50%). Neither imaging findings nor multidomain cognitive testing showed any substantive differences between APOE ε4 carriers and non‐carriers. Conclusion: We found no evidence of neurodegenerative risk from APOE ε4 in American Indians. Additional studies are needed to examine potential protective features.